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Human cell lines established from biliary tract cancers are rare, and only ﬁve have been reported previously. We report the
characterisation of six new six biliary tract cancer cell lines (designated SNU-245, SNU-308, SNU-478, SNU-869, SNU-1079
and SNU-1196) established from primary tumour samples of Korean patients. The cell lines were isolated from two
extrahepatic bile duct cancers (one adenocarcinoma of common bile duct, one hilar bile duct cancer), two adenocarcinomas
of ampulla of Vater, one intrahepatic bile duct cancer (cholangiocarcinoma), and one adenocarcinoma of the gall bladder. The
cell phenotypes, including the histopathology of the primary tumours and in vitro growth characteristics, were determined. We
also performed molecular characterisation, including DNA ﬁngerprinting analysis and abnormalities of K-ras, p15, p16, p53,
hMLH1, hMSH2, DPC4, b-catenin, E-cadherin, hOGG1, STK11, and TGF-bRII genes by PCR–SSCP and sequencing analysis. In
addition, we compared the genetic alterations in tumour cell lines and their corresponding tumour tissues. All lines grew as
adherent cells. Population doubling times varied from 48–72 h. The culture success rate was 20% (six out of 30 attempts). All
cell lines showed (i) relatively high viability; (ii) absence of mycoplasma or bacteria contamination; and (iii) genetic
heterogeneity by DNA ﬁngerprinting analysis. Among the lines, three lines had p53 mutations; and homozygous deletions in
both p16 and p15 genes were found three and three lines, respectively; one line had a heterozygous missense mutation in
hMLH1; E-cadherin gene was hypermethylated in two lines. Since the establishment of biliary tract cancer cell lines has been
rarely reported in the literature, these newly established and well characterised biliary tract cancer cell lines would be very
useful for studying the biology of biliary tract cancers, particularly those related to hypermethylation of E-cadherin gene in
biliary tract cancer.
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The prognosis of patients with biliary tract cancer is poor despite
recent advances in diagnostic and therapeutic techniques (Yamada
et al, 1995; Yoshida et al, 1995). An understanding of the biolo-
gical nature of this neoplasm is needed to improve the prognosis
of these patients. For this purpose, a permanently growing cell
line can be the most suitable tool because it is applicable to a
variety of experiments, including the understanding of tumour
biology (Yano et al, 1992; Yamada et al, 1995). However, biliary
tract cancer cell lines are very rare, a total of 13 cell lines have
been reported in the literature. Gene alterations involving in carci-
nogenesis and cancer progress in the cancers of alimentary tract
such as colorectal cancer and pancreatic cancer have been known.
However, in biliary tract cancers, few reports have shown genetic
changes responsible for oncogene and tumour suppressor gene
(Yoshida et al, 1995). In the present study, we report the estab-
lishment and characterisation of six new human biliary tract
cancer cell lines (designated SNU-245, SNU-308, SNU-478,
SNU-869, SNU-1079 and SNU-1196). We described cell pheno-
types including the in vivo and in vitro growth characteristics,
and DNA proﬁles for authenticity of each line. We also checked
genetic alterations of K-ras, p15, p16, p53, hMLH1, hMSH2,
DPC4, STK11, E-cadherin, hOGG1, TGF-bRII genes and compared
the genetic alterations in tumour cell lines and their correspond-
ing tumour tissues. In these biliary tract cancer cell lines, the
methylation status of promoter region in E-cadherin gene was also
investigated by 5-aza-2'-deoxycytidine treatment and methylation
speciﬁc-polymerase chain reaction (MS-PCR) after sodium bisul-
phite treatment.
MATERIALS AND METHODS
Cell culture
Cell lines were established from pathologically proven primary bili-
ary tract and ampulla of Vater cancer samples of six Korean
patients. Of these, two cancer cell lines originated in extrahepatic
bile duct cancer, one in intraheatic bile duct cancer, and one in
adenocarcinoma of gall bladder, and two in ampulla of Vater
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www.bjcancer.comcancer. Solid tumours were ﬁnely minced with scissors and dis-
associated into small aggregates by pipetting. Appropriate amounts
of ﬁnely minced neoplastic-tissue fragments were seeded into
25 cm
2 ﬂasks. Tumour cells were initially cultured in ACL-4
medium supplemented with 5% heat-inactivated foetal bovine
serum (AR5) (Park et al, 1987, 1995). After establishment, cultures
were maintained in RPMI 1640 supplemented with 10% heat-
inactivated foetal bovine serum. If stromal-cell growth was noted
in initial cultures, differential trypsinisation was used to obtain a
pure tumour-cell population. Cultures were maintained in humidi-
ﬁed incubators at 378C in an atmosphere of 5% CO2 and 95% air.
A-431, HeLa, and K-562 cell lines from the American Type Cell
Culture (ATCC) and SNU-1 cell line from Korean Cell Line Bank
(KCLB) were used for PCR controls. For growth properties and
morphology study in vitro, population doubling times and cell
viability were determined and cells grown on 75-cm
2 culture ﬂasks
were observed daily by phase-contrast microscopy (Park et al,
1995).
Nucleic acid isolation, cDNA synthesis and DNA proﬁles
Genomic DNA and total RNA were isolated from washed-cell
pellets. cDNA was synthesised according to the manufacturer’s
speciﬁcations (Power cDNA synthesis kit; Intron Biotechnology,
Seoul, Korea) using 2 mg of total RNA. To compare the genetic
alterations between established tumour cell lines and their corre-
sponding tumour tissues, we obtained DNAs from microdissected
tumour cells and stromal cells in H&E stained slides of correspond-
ing tumour tissues of each tumour cell line. Approximately 500–
1000 dissected tumour or stromal cells were digested using protei-
nase K method described previously (Hung et al, 1995). For DNA-
proﬁle analysis, DNA was ampliﬁed by PCR at loci containing
highly polymorphic microsatellite markers: D1S1586 and
D3S1765 (Ku et al, 1999).
Mutation screening in K-ras, p53, p15, p16, hMLH1 and
hMSH2 genes
Mutation screening of exons 1 and 2 of K-ras was performed by
DNA sequencing analysis using oligonucleotide primers as
previously described (Capon et al, 1983). Mutational screening
of exons 5 to 8 of p53 was performed by PCR-based single
strand conformation polymorphism (PCR-SSCP) analysis (Kang
et al, 1996). Primers for PCR-SSCP for exons 1 and 2 of the
p15 gene were synthesised (Orlow et al, 1995), and PCR-SSCP
primers for exons 1 and 2 of p16 gene were carried out as
described previously (Williamson et al, 1995). For deletion analy-
sis of the p15 and p16 genes, we ampliﬁed the exons of each
gene without [a-
32P]-dCTP. To investigate the genetic status of
hMSH2 and hMLH1 genes in biliary tract cancer cell lines,
PCR-SSCP analysis was used to screen mutations (Liu et al,
1994; Han et al, 1996).
Mutation screening in b-catenin, DPC4, STK11, TGF-bRII,
and hOGG1 genes
PCR-SSCP analysis to screen mutations of the b-catenin gene was
carried out by designed-primers for ampliﬁcation of exons 3, 5,
and 6, since mutations reported earlier in the b-catenin gene are
concentrated at these exons (Kitaeva et al, 1997; Iwao et al,
1998). To investigate the genetic alteration of the DPC4 gene, we
screened 11 exons by PCR-SSCP (Hahn et al, 1998). For muta-
tional analysis of STK11 gene, the PCR primer pairs were used
as described previously (Jenne et al, 1998). Mutation screening of
the full seven exons of TGF-bRII gene was also performed by
PCR-SSCP analysis (Lu et al, 1996). For mutational analysis of
hOGG1 gene, PCR primer pairs and conditions were described
previously (Kohno et al, 1998).
Genetic alteration and methylation analysis of E-cadherin
gene
To investigate mutation, all 16 exons were screened by PCR-SSCP
(Berx et al, 1996). For determination of the methylation status in
E-cadherin gene, 5-aza-2'-deoxycytidine treatment and sodium
bisulphite modiﬁcation were employed. For 5-aza-2'-deoxycytidine
treatment, cells were seeded at 2610
5 cells 75-cm
2 culture ﬂask on
day 0. The cells were treated with 10 mm 5-aza-2'-deoxycytidine for
24 h on days 2 and 5. The medium was changed 24 h after adding
5-aza-2'-deoxycytidine. Cells were harvested on day 8 for analysis
of E-cadherin expression.
For mRNA expression analysis, cDNA was ampliﬁed in a 25 ml
PCR reaction using 0.75 ml of the reverse-transcription reaction,
the primers and 0.5 units of the Taq DNA polymerase. Both E-
cadherin and b-actin RT–PCR reactions used the same cDNA
synthesis. b-actin was ampliﬁed to control for RNA integrity.
The primers for the ampliﬁcation of E-cadherin gene mRNA were
described previously (Melki et al, 2000). Products were electro-
phoresed on a 2% agarose gel with ethidium bromide.
The sodium bisulphite reaction was carried out for 16 h at 558C.
Following bisulphite modiﬁcation, the DNA was ethanol precipi-
tated, dried, and resuspended in 100 ml distilled water. A nested
PCR was performed using the nested PCR primers as described
previously (Melki et al, 2000).
Cloning and sequencing
Samples showing abnormal bands by SSCP were subjected to DNA
sequencing analysis. Fresh PCR products were ligated into PCR
TMII
vectors and subcloned using the TA cloning system (Invitrogen,
San Diego, CA, USA). A minimum of 10 individual clones were
then pooled and used for DNA isolation. Bi-directional DNA
sequencing analysis performed by using dideoxy chain termination
method with a T7 DNA polymerase sequencing kit (Pharmacia
Biotech Inc., Piscataway, NJ, USA), or directly sequenced using a
Taq dideoxy terminator cycle sequencing kit on an ABI 377
DNA sequencer (Perkin-Elmer, Foster City, CA, USA).
RESULTS
Culture characteristics
Population doubling times ranged 48 to 72 h, and cell viability
ranged from 85 to 94% (Table 1). All the cell lines were free of
contamination with either bacteria or Mycoplasma. The culture
success rate was 20% (six out of 30 attempts).
Morphologic studies
Six carcinoma cell lines derived from biliary tract system were
established. The primary tumour of SNU-245 originated from the
distal common bile duct. Microscopically, the tumour was
composed of well-formed glands lined by a few rows of highly
atypical cuboidal cells with lumina containing oeosinophilic mate-
rial or necrotic cell debris and inﬁltrated to the stroma. Cell line
SNU-308 was established from an adenocarcinoma of a gall
bladder. Microscopically, the tumour was composed of well-differ-
entiated neoplastic glands or trabeculae. Two cases of ampulla of
Vater carcinoma were obtained from primary tumours. Microsco-
pically, the tumour of SNU-478 was poorly differentiated
adenocarcinoma with signet ring cell feature and inﬁltrated to
the pancreas along the interstitial space as a single cell or cell cords.
The tumour of SNU-869 was composed of well differentiated
adenocarcinoma with focal papillary feature. Five out of 10 peri-
duodenal lymph nodes were involved by this tumour and the
tumour inﬁltrated to the duodenal muscle layer and involved of
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the cholangiocarcinoma arising from right lobe of liver. Microsco-
pically, the tumour of SNU-1079 was composed of irregular nests
of tumour cells with focal glandular differentiation, which were
separated by ﬁbrous stroma. Cell line SNU-1196 was derived from
Klatskin tumour arising in the hepatic duct conﬂuence and invaded
to the both intrahepatic duct and common bile duct. Tumour cells
had large and vesicular nuclei, and micro or macronucleoli.
In culture, all the cell lines except SNU-478 grew as monolayer
of substrate-adherent cells. SNU-245 exhibited trabecular arrange-
ment with acinar formation (Figure 1A). Tumour cells of SNU-
308 was composed of polygonal and relatively uniform cells having
large, round to ovoid, vesicular nuclei with prominent nucleoli.
Acinar formation was focally seen (Figure 1B). SNU-478 showed
two distinct growth pattern, The cells growing as monolayer were
polygonal, and cells growing as spherical cells in suspension formed
grape-like clusters. The polygonal adherent cells of SNU-478
showed large, round to ovoid, vesicular nuclei with several nucleoli
(Figure 1C). SNU-869 composed of polygonal adherent cells grew
conﬂuently with frequent acinar formation and ﬂoating clumps of
tumour cells. SNU-1079 exhibited marked pleomorphic appearance
with multiple cytoplasmic processes. Multinucleated bizarre
tumour cells were frequently seen. Some cells had numerous cyto-
plasmic vacuoles. SNU-1196 forming trabecular pattern consisted
of spindle to polygonal shaped cells having vesicular nuclei and
multiple small nucleoli.
DNA proﬁles
DNA proﬁles using two highly polymorphic microsatellite markers
(D1S1586 and D3S1765) showed that six biliary tract carcinoma
cell lines are unique and unrelated (Figure 2). These results help
exclude the possibility of cross-contamination between the cell
lines, as well as by HeLa cell line.
Mutations in the p53, p15, p16 and hMLH1 genes
For p53 gene, SNU-478 had an adenine insertion at codon 266 of
exon 8 resulting in a premature stop codon (TGA) at 12 bp down-
stream (Figure 3): SNU-869 harboured a missense mutation from
aspartic (GAC) acid to glycine (GGT) at codon 48 of exon 4;
SNU-1196 had a missense mutation from asparagine (CGT) to
cysteine (TGT) at codon 273 of exon 8. A summary of the results
appears in Table 2.
There were no band shifts in p15 and p16 genes by PCR-PCR
SSCP analysis. However, there were no PCR ampliﬁcations in three
lines (SNU-478, SNU-1079, and SNU-1196). By based deletion
analysis of each gene, we found that exon 1 of p15 gene was not
ampliﬁed in three cell lines (SNU-478, SNU-1079 and SNU-
1196) and exon 2 of this gene was not ampliﬁed in two cell lines
(SNU-478 and SNU-119). We also found that exons 1 and 2 of p16
gene were not ampliﬁed in three cell lines (SNU-478, SNU-1079
and SNU-1196) (Figure 4). The results were listed (Table 2).
In hMLH1 mutational analysis, only SNU-478 harboured a
heterozygous missense mutation from GAT to GTT at codon 384
of exon 12, with resultant amino acid change from aspartic acid
to valine (data not shown).
Mutation analysis in b-Catenin, DPC4, hOGG1, STK11, and
TGF-bRII genes
There were no abnormal band shift bands in the b-catenin, DPC4,
STK11, and TGF-bRII genes by PCR-SSCP analysis. In hOGG1
gene, 4 lines (SNU-308, SNU-478, SNU-869 and SNU-1079) were
found to harbour abnormal band shift bands in exon 5. By the
direct sequencing of DNA fragments corresponding to shifted
bands, a C?G nucleotide change at 715 bp from exon 5 was
found in all four lines (Table 2).
mRNA expression and methylation analysis in E-cadherin
gene
By PCR-SSCP for all 16 exons, abnormal band shifts were not
found in all cases. To determine the expression of E-cadherin gene
in six biliary tract cancer cell lines, we used RT–PCR analysis.
SNU-1 and A-431 cell lines were used for negative and positive
controls for the expression of E-cadherin mRNA. As shown in
Figure 5, SNU-245, SNU-308, SNU-869, SNU-1196 and control
(A-431) cell lines expressed E-cadherin mRNA, whereas SNU-478,
SNU-1079 and control (SNU-1) cell lines showed absence of
expression (Figure 5A). Therefore, we determined the methylation
status by 5-aza-2'-deoxycytidine treatment and sodium bisulphite
modiﬁcation in these cell lines. After 5-aza-2'-deoxycytidine treat-
ment, E-cadherin mRNA was reexpressed in SNU-478, SNU-1079
and control (SNU-1) cell lines (Figure 5B). Methylation speciﬁc
PCR analysis for CpG island of promoter region in the E-cadherin
gene after sodium bisulphite modiﬁcation, DNA fragments were
ampliﬁed in only SNU-478, SNU-1079 and SNU-1 cell lines
(Figure 5C).
Comparison of genetic alterations in tumour cell lines and
their corresponding tumour tissues
Of six biliary tract cancer cell lines, parafﬁn blocks from four cell
lines (SNU-245, SNU-308, SNU-869 and SNU-1079) were avail-
able. Tumour cells and stromal cells were dissected, respectively,
and DNAs were extracted from these samples. Genetic alterations
in DNA of tumour cells were identical to those that had found
in tumour cell lines and there were no mutations in constitutional
DNAs (data not shown).
DISCUSSION
Advances in cell culture methods have made it possible to establish
a variety of human carcinoma cell lines from surgical and autopsy
tissues, peritoneum effusion, and biopsy specimens (Yano et al,
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Table 1 In vivo and in vitro characteristics of biliary tract cancer cell lines
In vivo In vitro
Cell Degree of Nodal Growth Viability Doubling Cell Nuclear Prior
line Origin
a differentiation status
b characteristics
c (%) time (h) morphology morphology chemotherapy
SNU-245 CBD Well 0/9 Ad 85 54 Polygonal Single None
SNU-308 GB Moderately – Ad 88 48 Polygonal Single None
SNU-478 AV Poorly 0/8 Ad 83 52 Polygonal/spherical Single/multiple None
SNU-869 AV Well 5/10 Ad 91 48 Polygonal Single None
SNU-1079 IHD Moderately – Ad 89 72 Pleomorphic Single/multiple None
SNU-1196 HDB Moderately 0/1 Ad 94 48 Spindle to polygonal Single None
aCBD=common bile duct, GB=gall bladder, AV=ampulla of Vater, IHD=intrahepatic duct, HDB=hepatic duct bifurcation.
bMetastasis/total.
cAd=adherent.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 187–1931992; Yamada et al, 1995). Moreover, because pure cells in cultures
can be used for a variety of studies that cannot be carried out using
tissue specimens, the study of permanent cell lines established form
human cancers has played a major role in our understanding of the
biology of cancers. However, cell lines originated from biliary tract
cancers have rarely been reported. Ten human extrahepatic bile
duct carcinoma cell lines (SK-ChA-1 (Knuth et al, 1985), KMBC
(Yano et al, 1992), and OCUCh-LM1 (Yamada et al, 1995),
TFK-1 (Saijyo et al, 1995), ICBD-1 (Takiyama et al, 1998), HBDC
(Jiao et al, 2000), SCK, JCK, Cho-CK, Choi-CK (Kim et al, 2001a))
and three gall bladder carcinoma cell lines (MZ-ChA-1 and Mz-
ChA-2 (Knuth et al, 1985), OCUG-1 (Yamada et al, 1997) have
been reported in the world literature.
In this paper, we present six newly established biliary tract
cancer cell lines derived from histopathological varied primary
carcinomas including a distal common bile duct, gallbladder, two
ampulla of Vater, an intrahepatic duct, and a hepatic duct bifurca-
tion tumour. The culture success rate of 20%, reﬂecting the relative
high efﬁciency of AR5 medium in selective growth of human bili-
ary tract cancers, although the establishment of cell lines from
biliary tract cancers, especially cell lines from primary tumours,
is very difﬁcult as described above.
Primary tumours revealed morphological heterogeneity includ-
ing cellular and a growth pattern of original tumours in each
tumour type. Cell lines derived from primary biliary tract cancer
showed marked heterogeneity in cellular and nuclear morphology,
and growth pattern in vitro. All six cell lines grew as adherent
monolayer, of these, SNU-869 formed prominent domes.
In biliary tract cancers, the role of p53 is still controversial and
mutation rate of this gene varied from 33 to 65% according to
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Figure 1 (A) Cultured cells of SNU-245 are polygonal shaped adherent
cells and arranged in a trabecular pattern with acinar formation. (B) Phase-
contrast microscopy of SNU-308 cell lines showed polygonal shaped
adherent cells with large, round to ovoid, and vesicular nuclei. (C) Cultured
cells of SNU-478 showed two distinct growth groups:the one growing as a
monolayer is polygonal, and the other growing as spherical cells in
suspension forms grape-like clusters. Scale bars=50 mM.
1    2    3    4      5      6     7      8 1    2      3    4    5    6       7      8
D1S1586 D3S1765
Figure 2 DNA ﬁngerprinting analysis of biliary tract cancer cell lines
using highly polymorphic microsatelilte markers. Lane numbers 1 to 8 show
cell lines SNU-245, SNU-308, SNU-478, SNU-869, SNU-1079, SNU-1196,
HeLa, K-562, and water only. It is evident that each of the six SNU biliary
tract cancer cell lines is unique and unrelated.
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Figure 3 PCR-SSCP and DNA sequencing analysis of exon 8 in the p53
gene. (left) PCR-SSCP analysis of exon 8. Arrows indicate the shifted bands
in SNU-478, as compared with the normal mobility in other cell lines.
(right) DNA sequencing analysis of SNU-478.
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Korean, it was reported that 35.7% had mutations in this gene
(Kim et al, 2001b). In newly established six cell lines, we detect
two missense mutations and one frameshift mutation (50%). Two
mutations were found to be in exon 8 and one mutation in exon 4.
p15 and p16 genes belonging to the cyclin-dependent kinase 4
inhibitory family, have homology and are adjacent to each other.
In our six cell lines, simultaneously homozygous deletions of p15
and p16 genes, but no point mutation, were found in (SNU-478,
SNU-1079 and SNU-1196). In SNU-1079, exon 1 of p15 gene
was deleted and exon 2 was intact. These results indicate that
p15 and p16 are homozygously deleted preferentially in the region
neighbouring the two genes in biliary tract cancer cell lines. Kim et
al (2001) reported that 30.7% of this gene was mutated in gall
bladder carcinomas from Korean. Moreover, the high frequency
of deletions of p15 and p16 in cell lines indicate the possibility
of these genes functioning as tumour suppressor genes in biliary
tract cancer as described previously (Yoshida et al, 1995).
We also found one heterozygous missense mutation at codon
384 of exon 12 in hMLH1 gene in one cell line (SNU-478). We
screened the microsatellite instability (MSI) status in this line using
several MSI markers such as BAT-25, BAT-26 and BAT-40 which
were used as a surrogate to indicate MSI status, but failed to ﬁnd
evidence of MSI (Myeroff et al, 1995). Although we didn’t check
this mutation in normal counterpart because of no availability
normal tissue, we think that this mutation is polymorphism
because this cell line did not show MSI.
A signiﬁcant number of human carcinomas and cancer cell
lines lose sensitivity to negative growth regulation by transform-
ing growth factor b (TGF-b) (Vincent et al, 1997). In biliary
tract cancers, it was reported that 16% (ﬁve out of 32 primary
biliary carcinomas) had point mutations in the DPC4 gene (Hahn
et al, 1998). In our cell lines, we had not found shifted bands in
all samples by PCR-SSCP analysis. Moreover, we found that all
cell lines expressed intact DPC4 mRNA (data not shown). In
addition, we did not ﬁnd genetic alterations in TGF-bRII gene
by PCR-SSCP and RT–PCR analysis, although genetic alterations
of the TGF-bRII gene in biliary tract cancers have been reported
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Table 2 Abnormalities of the p15, p16, p53, K-ras, hMLH1, E-cadherin, hOGG1, b-catenin, DPC4, STK11 and TGF-bRII genes in SNU biliary tract cancer cell
lines
Cell K-ras gene
E-cadherin
line p15 gene p16 gene p53 gene (exon 1) MLH1 gene Mutation Expression 5-aza MS-PCR hOGG1
SNU-245 WT WT WT WT WT WT + + 7 WT
SNU-308 WT WT WT WT WT WT + + 7 IVS4-15C4G
SNU-478 Deletion Deletion 266-267insT WT Asp384Val WT 7 + + IVS4-15C4G
SNU-869 WT WT Asp48Gly WT WT WT + + 7 IVS4-15C4G
SNU-1079 Deletion (exon 1) Deletion WT WT WT WT 7 + 7 IVS4-15C4G
SNU-1196 Deletion Deletion Arg273Cys WT WT WT + + + WT
WT=mutations was not detected. 5-aza=RT–PCR after 5-aza-2'-deoxycytidine treatment. MS-PCR=methylation speciﬁc PCR. +=expression. 7=no expression. In the p15
gene, the exon 1 was only detected in SNU-1079 cell line. Mutations were not detected in K-ras, b-catenin, DPC4, STK11 and TGF-bRII genes.
(A) Exon 1
 M   1     2    3    4    5   6   7    8 DW
(D) Exon 1
  M   1     2    3    4    5   6   7    8 DW
(B) Exon 2 (E) Exon 2
(C) K-ras (F) K-ras
Figure 4 PCR-based deletion analysis of the p15 and p16 genes. (A,B)
PCR ampliﬁcation of the p15 gene. (C) PCR ampliﬁcation of exon 2 in the
K-ras gene used as internal control for separate PCR ampliﬁcation. (D,E)
PCR ampliﬁcation of the p16 gene. (F) K-ras gene for internal control
for separate PCR ampliﬁcation. Lane numbers 1 to 9 show cell lines
SNU-245, SNU-308, SNU-478, SNU-869, SNU-1079, SNU-1196, HeLa,
K-562, and water only.
(A) RT–PCR for E-cadherin
   M       1       2        3       4        5       6       7       8    DW
b-actin
(B) RT–PCR after 5-azacytidine treat
   M      1       2      3        4       5       6        7       8   DW
b-actin
(C) Methylation specific PCR
Figure 5 Hypermethylation of E-cadherin gene in SNU-biliary tract
cancer cell lines. (A) RT–PCR analysis of E-cadherin gene. Lane numbers
(1–9) indicate cell lines: SNU-245, SNU-308, SNU-478, SNU-869, SNU-
1079, SNU-1196, SNU-1 (gastric carcinoma cell line, positive control for
methylation of E-cadherin gene, A-431(negative control), and water only.
b-actin is RT–PCR control for mRNA expression. (B) RT–PCR analysis
after 5-aza-2'-deoxycytidine treatment. It is note that E-cadherin gene is
re-expressed after 5-aza-2'-deoxycytidine treatment. b-actin is RT–PCR
control for mRNA expression. (C) Methylation speciﬁc PCR analysis after
sodium bisulphite modiﬁcation. It is evident that SNU-478 and SNU-1079
lines are methylated in CpG island of promoter region in the E-cadherin
gene.
Human biliary tract cancer cell lines
J-L Ku et al
191
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 187–193in some (Goggins et al, 1998; Yazumi et al, 2000). We think that
our results in six cancer cell lines do not relfect differences in
genetics of biliary tract cancers in Korean because the sample size
is too small, although we did not found any reports about muta-
tions of DPC4 and TGF-bRII genes in biliary tract cancers in
Korean.
E-cadherin gene on chromosome 16q22.1 encodes a protein
product important in the maintenance of the epithelial phenotype
mediated by a Ca
2+-dependent, homotypic cell–cell adhesion. The
gene has been termed a ‘metastasis suppressor’ gene, because the E-
cadherin protein can suppress tumour cell invasion and metastasis.
E-cadherin gene expression is reduced or silenced in carcinomas of
the breast and liver and many cell lines including those from colon,
stomach, and prostate (reviewed by Melki et al, 2000). Alterations
in DNA methylation patterns are commonly found in essentially all
cancers, often with concomitant changes in gene expression. In our
study, we have not found mutations in all 16 exons of E-cadherin
gene by PCR-SSCP. However, we found that E-cadherin gene
expression was silenced in two cell lines (SNU-478 and SNU-
1079) by RT–PCR analysis (Figure 5A). After demethylating agent
(5-aza-2'-deoxycytidine) treatment, E-cadherin was successfully
reexpressed in these two cell lines (Figure 5B). Hypermethylation
of E-cadherin gene in two cell lines have also been conﬁrmed by
methylation speciﬁc PCR (MS-PCR) analysis (Figure 5C). These
results would be the ﬁrst report about hypermethylation of E-
cadherin gene in biliary tract cancers.
Since the establishment of biliary tract cancer cell lines has been
rarely reported in the literature, these well-characterised biliary
tract cancer cell lines will be useful tools for investigating the biolo-
gical characteristics of biliary tract cancer, especially those related
to the hypermethylation of E-cadherin gene in biliary tract cancers.
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